Results 71 to 80 of about 9,340 (184)

Ratio of plasma IL-13/TNF- ∝ and CXCL10/CCL17 predicts mepolizumab and omalizumab response in asthma better than eosinophil count or immunoglobulin E level

Scientific Reports
To date, most studies to identify biomarkers associated with response to the anti-interleukin 5 agent, mepolizumab, and to the anti-immunoglobulin E agent, omalizumab have focused on clinically available biomarkers, such as the peripheral blood ...
Ayobami Akenroye, Tanawin Nopsopon, Jonathan J. Hacker, Tanya M. Laidlaw   +3 more
doaj   +1 more source

Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs

Journal of Asthma and Allergy, 2020
Jean-Pierre Llanos,1 Hector Ortega,1 Michael Bogart,2 Elizabeth R Packnett,3 Janna Manjelievskaia,3 Christopher F Bell,2 Beth Hahn2 1Respiratory, US Medical Affairs, GSK, Research Triangle Park, NC, USA; 2US Value Evidence and Outcomes, US Medical ...
Llanos JP, Ortega H, Bogart M, Packnett ER, Manjelievskaia J, Bell CF, Hahn B   +6 more
doaj  

Dupilumab‐Related Adverse Events and Intolerance in Aspirin‐Exacerbated Respiratory Disease Patients

International Forum of Allergy &Rhinology, Volume 16, Issue 4, Page 413-417, April 2026.
Lancelot P. Herpin, Randy Bach, Ricardo Bruneto, Kerol A. Faltas, Michael A. Kohanski, James N. Palmer, Nithin D. Adappa, Jennifer E. Douglas, John V. Bosso   +8 more
wiley   +1 more source

Evaluation of Clinical Remission in Best-Performing Severe Asthmatic Patients Treated for Three Years with Mepolizumab

Biomedicines
Background: In its severe form, where possible, asthma is treated using biological drugs in order to reduce, as much as possible, the use of systemic steroids.
D. Bagnasco, Benedetta Bondi, M. Caminati, Stefania Nicola, L. Pini, M. Milanese, L. Brussino, G. Senna, G. W. Canonica, Fulvio Braido   +9 more
semanticscholar   +1 more source

Mepolizumab [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

Peak nasal inspiratory flow assessment of polyp size and response from SYNAPSE

Journal of Allergy and Clinical Immunology: Global
Background: In the phase III SYNAPSE study, mepolizumab plus standard of care reduced total endoscopic nasal polyp score (NPS) versus that with placebo in patients with chronic rhinosinusitis with nasal polyps.
Amber U. Luong, MD, PhD, Joshua M. Levy, MD, MPH, MSc, Ludger Klimek, MD, PhD, Richard J. Harvey, MD, Jared Silver, MD, PhD, Steven G. Smith, PhD, Abby Fuller, MSc, Robert Chan, MD, Peter W. Hellings, MD, PhD   +8 more
doaj   +1 more source

Dupilumab versus mepolizumab for chronic rhinosinusitis with nasal polyposis: an indirect treatment comparison.

Journal of Allergy and Clinical Immunology: In Practice
BACKGROUND Dupilumab and mepolizumab have shown efficacy and safety in treating chronic rhinosinusitis with nasal polyps (CRSwNP). OBJECTIVE Without available results from head-to-head randomized control trials (RCTs) comparing dupilumab with other ...
Claire Hopkins, Joseph K. Han, W. Fokkens, M. Wagenmann, P. Guyot, Asif H Khan, S. Nash, Zhixiao Wang, Yingxin Xu, J. Msihid, B. Neupane, Arpita Nag, C. Bachert   +12 more
semanticscholar   +1 more source

Real-Life Evidence of Mepolizumab Treatment in Chronic Rhinosinusitis with Nasal Polyps: A Multicentric Study

Journal of Clinical Medicine
Background: The introduction of biological drugs in the management of chronic rhinosinusitis with nasal polyps (CRSwNP) is allowing new and increasingly promising therapeutic options.
C. Cavaliere, A. Loperfido, A. Ciofalo, Loreta Di Michele, E. Begvarfaj, G. Bellocchi, Marcella Bugani, M. de Vincentiis, Antonio Greco, Stefano Millarelli, Michaela Plath, Eleonora Sculco, S. Masieri   +12 more
semanticscholar   +1 more source

Budget Impact Analysis of Mepolizumab for Eligible Patients in the Setting of a Severe Asthma Clinic Within Dubai Health Authority (DHA)

ClinicoEconomics and Outcomes Research, 2022
Bassam Mahboub,1 Ahmed Mohy,2 Islam El-Amir,2 Tamara Lukić,3 Raef Gouhar,4 Saeed Noibi5 1Pulmonary Medicine Department, Rashid Hospital, Dubai Health Authority, Dubai, United Arab Emirates; 2Medical Affairs Department, GSK, Jeddah, Kingdom of ...
Mahboub B, Mohy A, El-Amir I, Lukić T, Gouhar R, Noibi S   +5 more
doaj  

Patients taking benralizumab, dupilumab, or mepolizumab have lower postvaccination SARS-CoV-2 immunity.

Journal of Allergy and Clinical Immunology
BACKGROUND Biologic therapies inhibiting the IL-4 or IL-5 pathways are very effective in the treatment of asthma and other related conditions. However, the cytokines IL-4 and IL-5 also play a role in the generation of adaptive immune responses.
M. Runnstrom, Pedro A. Lamothe, C. Faliti, N. Cheedarla, A. Moreno, M. Suthar, R. Nahata, M. Ravindran, N. Haddad, A. Morrison-Porter, H. Quehl, R. Ramonell, M. Woodruff, F. Anam, Rebeca Zhang, C. Swenson, C. Polito, W. Neveu, R. Patel, N. Smirnova, Doan C. Nyugen, Caroline Kim, I. Hentenaar, Shuya Kyu, S. Usman, T. Ngo, Zhenxing Guo, Hao Wu, J. Daiss, Jiwon Park, K. Manning, Bursha Wali, M. Ellis, Sunita Sharma, Fernando Holguin, S. Cheedarla, A. Neish, John D Roback, Ignacio Sanz, F. Eun-Hyung Lee   +39 more
semanticscholar   +1 more source